{"Clinical Trial ID": "NCT00191854", "Intervention": ["INTERVENTION 1:", "- Gemcitabine + Paclitaxel", "Gemcitabine: 2500 milligrams per square metre (mg/m2), intravenously (IV), every 14 days x 8 cycles.", "Paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles", "INTERVENTION 2:", "- Gemcitabine + Carboplatin", "Gemcitabine: 2500 milligrams per square metre (mg/m2), intravenously (IV), every 14 days x 8 cycles.", "Carboplatin: Area under curve (AUC) 2.5, IV, every 14 days x 8 cycles"], "Eligibility": ["Incorporation criteria:", "Women with a proven histological or cytological diagnosis of breast cancer", "Stage IV typology", "\u2022 Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale", "Patients were expected to have already received anthracycline-based treatments in the form of adjuvant or neo-adjuvant chemotherapy, and then progressed and developed metastatic disease.", "Adequate function of the organ", "- Exclusion criteria:", "Previous chemotherapy for metastatic disease", "Prior radiation therapy is permitted but must not have included whole-basin radiation.", "\u2022 Serious concurrent disorders that would compromise the patient's safety or compromise the patient's ability to complete the study, at the discretion of the investigator", "Concomitant administration of any other tumour therapy, including cytotoxic chemotherapy, hormone therapy and immunotherapy (including trastuzumab (Herceptin))", "\u00b7 Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorders, including seizures or dementia"], "Results": ["Performance measures:", "Best overall response", "Complete response=disappearance of all target lesions; Partial response=30% decrease in the sum of the longest diameter of target lesions; Progressive illness=20% increase in the sum of the longest diameter of target lesions; Stable illness=small changes that do not meet the above criteria.", "Time: start of progressive disease measured (student tumour assessments were performed every 4 cycles during study treatment, or 3 months after treatment until disease progression, death or up to 24 months after randomization)", "Results 1:", "Title of arm/group: Gemcitabine + Paclitaxel", "Description of the arm/group: Gemcitabine: 2500 milligrams per square metre (mg/m2), intravenous (IV), every 14 days x 8 cycles.", "Paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles", "Total number of participants analysed: 49", "Type of measurement: Number", "Unit of Measure: Participants Complete Response (CR): 1", "- Partial response (PR): 12", "Stable disease (SD): 17", "Progressive diseases (PD): 14", "Early Deaths for Other Causes: 1", "Unknown: 4", "Results 2:", "Title of arm/group: Gemcitabine + Carboplatin", "Description of the arm/group: Gemcitabine: 2500 milligrams per square metre (mg/m2), intravenous (IV), every 14 days x 8 cycles.", "Carboplatin: Area under curve (AUC) 2.5, IV, every 14 days x 8 cycles", "Total number of participants analysed: 47", "Type of measurement: Number", "Unit of Measure: Participants Complete Response (CR): 0", "- Partial response (PR): 8", "Stable disease (SD): 25", "Progressive diseases (PD): 11", "Early Deaths of Other Causes: 2", "Unknown: 1"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/49 (10.20 per cent)", "Anemia 1/49 (2.04%)", "Leucopenia 21/49 (2.04%)", "Neutropenia 30/49 (0.00 %)", "Thrombocytopenia 31/49 (2.04%)", "Pyrexia 1/49 (2.04%)", "- Sudden death 31/49 (2.04%)", "Hepatic impairment 0/49 (0.00 %)", "Anaphylactic reaction 1/49 (2.04%)", "Cystitis 31/49 (2.04%)", "- Pneumonia 40/49 (0.00 %)", "Pyelonephritis 0/49 (0.00 %)", "- Sepsis 30/49 (0.00 per cent)", "Adverse Events 2:", "Total: 3/47 (6.38 per cent)", "Anemia 0/47 (0.00 %)", "- Leucopenia 20/47 (0.00 per cent)", "Neutropenia 31/47 (2.13 per cent)", "Thrombocytopenia 31/47 (2.13 per cent)", "Pyrexia 0/47 (0.00 %)", "\u2022 Sudden death 30/47 (0.00%)", "Hepatic impairment 1/47 (2.13 per cent)", "Anaphylactic reaction 0/47 (0.00 %)", "Cystitis 30/47 (0.00 per cent)", "Pneumonia 41/47 (2.13 per cent)", "Pyelonephritis 1/47 (2.13 per cent)", "Sepsis 31/47 (2.13 per cent)"]}